Strona glówna
•
FAQ
•
Szukaj
•
Użytkownicy
•
Grupy
•
Galerie
•
Rejestracja
•
Profil
•
Zaloguj się, by sprawdzić wiadomości
•
Zaloguj
Forum Forum MESA !! Strona Główna
->
Polonia Bytom
Napisz odpowiedź
Użytkownik
Temat
Treść wiadomości
Emotikony
Więcej Ikon
Kolor:
Domyślny
Ciemnoczerwony
Czerwony
Pomarańćzowy
Brązowy
Żółty
Zielony
Oliwkowy
Błękitny
Niebieski
Ciemnoniebieski
Purpurowy
Fioletowy
Biały
Czarny
Rozmiar:
Minimalny
Mały
Normalny
Duży
Ogromny
Zamknij Tagi
Opcje
HTML:
TAK
BBCode
:
TAK
Uśmieszki:
TAK
Wyłącz HTML w tym poście
Wyłącz BBCode w tym poście
Wyłącz Uśmieszki w tym poście
Kod potwierdzający: *
Wszystkie czasy w strefie EET (Europa)
Skocz do:
Wybierz forum
Nabór do ZESPÓŁ Forum MESA
----------------
Nabór
MESA - DRUŻYNY
----------------
GKS Bełchatów
Cracovia Kraków
Dyskobolia Grodzisk Wielkopolski
Górnik Zabrze
Jagiellonia Białystok
Korona Kielce
Lech Poznań
Legia Warszawa
ŁKS Łódź
Odra Wodzisław Śląski
Polonia Bytom
Ruch Chorzów
Wisła Kraków
Zagłębie Lubin
Zagłębie Sosnowiec
MESA - OGÓLNIE
----------------
Regulamin
Terminarz
Sędziowie
Wyniki
DLA KIBICA
----------------
Typer
Rozrywka
Sonda
INNE
----------------
Hydepark
Reklama
PARTNERZY
----------------
Parnerzy w reklamie i realizacji projektu !!
Przegląd tematu
Autor
Wiadomość
98c07fyn83jh
Wysłany: Czw 6:06, 13 Sty 2011
Temat postu: WuXi PharmaTech Well Positioned to Continue Growin
WuXi PharmaTech (Cayman) Inc. (NYSE: WX) announced today that its previously announced transaction with Charles River Laboratories International Inc. (NYSE: CRL) has been terminated by mutual agreement due to Charles River shareholder opposition. Under the terms of the termination agreement, WuXi will receive a breakup fee of $30 million.
"WuXi‘s strategy has not changed. Our goal is, and has long been,
Data convention outsourcing
, to build a broad, integrated R&D service platform designed to help our customers improve the success of research and shorten the time of new product development," said Dr. Ge Li, Chairman and Chief Executive Officer. "While we are disappointed that this transaction could not be completed, WuXi remains well positioned to meet our customers‘ needs and to continue to grow and expand as a standalone company.
"All of our businesses are performing very well," Dr. Li continued. "Each business unit has met or exceeded its targets for the second quarter,
Mobile solution
, and we recently increased our guidance for full-year 2010 financial performance.
"Virtually all of the large global pharmaceutical companies,
hospitality solution
, as well as hundreds of smaller pharmaceutical and biotech companies and many leading medical device companies, are our customers," Dr. Li concluded. "We believe that strong trends for greater outsourcing and offshoring of R&D services will continue, and that WuXi,
Business process outsourcing
, as the leading China-based contract research organization, is well positioned to benefit from this powerful outsourcing trend for many years to come."
Second Quarter Results
WuXi will report financial results for the second quarter ending June 30, 2010, on Monday,
health care outsourcing
, August 2, at 6:30 am EDT with a conference call at 8:30 am EDT to discuss the results and the outlook for WuXi‘s business. The conference call may be accessed by calling:
United States: 1-866-519-4004
China (Landline): 800-819-0121
China (Mobile): 400-620-8038
Hong Kong: 800-930-346
United Kingdom: 0-808-234-6646
International: +65-6723-9381
Conference ID: 90840146
Web PIN: 8656
A replay will be available two hours after the call‘s completion at:
United States: 1-866-214-5335
China North: 10-800-714-0386
China South: 10-800-140-0386
Hong Kong: 800-901-596
United Kingdom: 0-800-731-7846
International: +61-2-8235-5000
Passcode: 90840146
A live webcast of the conference call and replay will be available on the investor relations page of WuXi PharmaTech‘s website at .
fora.pl
- załóż własne forum dyskusyjne za darmo
Theme
FrayCan
created by
spleen
&
Download
Powered by
phpBB
© 2001, 2005 phpBB Group
Regulamin